Login to Your Account



Galapagos Scores Biggest Deal Yet: €400M Pact with Roche

By Nuala Moran


Wednesday, January 13, 2010

LONDON - Galapagos NV cemented its reputation as a drug discovery partner of choice for big pharma, signing a potential €400 million (US$579.6 million) deal with F. Hoffmann-La Roche Ltd. in both small-molecule and antibody treatments for chronic obstructive pulmonary disease (COPD). (BioWorld International)

 

BioWorld International Correspondent

 

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription